GNOG.L vs. URNG.L

Last updated Jun 5, 2026

GNOG.L (Global X Genomics & Biotechnology UCITS ETF) and URNG.L (Global X Uranium UCITS ETF USD Accumulating) are both exchange-traded funds - GNOG.L is a Health & Biotech Equities fund tracking the MSCI World/Health Care NR USD, while URNG.L is a Commodity Producers Equities fund tracking the Solactive Global Uranium & Nuclear Components. Both are passively managed. Over the past 3 years, GNOG.L returned -1.86%/yr vs 36.12%/yr for URNG.L. At a 0.35 correlation, their price movements are largely independent. GNOG.L charges 0.50%/yr vs 0.65%/yr for URNG.L.

Performance

GNOG.L vs. URNG.L - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in Global X Genomics & Biotechnology UCITS ETF (GNOG.L) and Global X Uranium UCITS ETF USD Accumulating (URNG.L). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GNOG.L achieves a 12.27% return, which is significantly lower than URNG.L's 18.27% return.

GNOG.L

• 1D: 5.70%
• 1M: 13.66%
• YTD: 12.27%
• 6M: 9.47%
• 1Y: 59.40%
• 3Y*: -1.86%
• 5Y*: —
• 10Y*: —

URNG.L

• 1D: -0.48%
• 1M: -7.77%
• YTD: 18.27%
• 6M: 7.25%
• 1Y: 64.64%
• 3Y*: 36.12%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOG.L vs. URNG.L - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
GNOG.L Global X Genomics & Biotechnology UCITS ETF	12.27%	12.03%	-16.98%	-11.35%	-0.47%
URNG.L Global X Uranium UCITS ETF USD Accumulating	18.27%	58.50%	2.96%	30.86%	-14.11%

Correlation

The correlation between GNOG.L and URNG.L is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.31
Correlation (3Y) Calculated over the trailing 3-year period	0.29
Correlation (All Time) Calculated using the full available price history since Apr 25, 2022	0.35

Return for Risk

GNOG.L vs. URNG.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOG.L

GNOG.L Risk / Return Rank: 62
GNOG.L Sharpe Ratio Rank: 66
GNOG.L Sortino Ratio Rank: 65
GNOG.L Omega Ratio Rank: 58
GNOG.L Calmar Ratio Rank: 70
GNOG.L Martin Ratio Rank: 52

URNG.L

URNG.L Risk / Return Rank: 37
URNG.L Sharpe Ratio Rank: 37
URNG.L Sortino Ratio Rank: 38
URNG.L Omega Ratio Rank: 36
URNG.L Calmar Ratio Rank: 40
URNG.L Martin Ratio Rank: 34

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOG.L vs. URNG.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology UCITS ETF (GNOG.L) and Global X Uranium UCITS ETF USD Accumulating (URNG.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GNOG.L	URNG.L	Difference
Sharpe ratio: Return per unit of total volatility	2.16	1.31	+0.85
Sortino ratio: Return per unit of downside risk	2.95	1.93	+1.02
Omega ratio: Gain probability vs. loss probability	1.35	1.23	+0.12
Calmar ratio: Return relative to maximum drawdown	3.44	1.97	+1.47
Martin ratio: Return relative to average drawdown	8.72	5.06	+3.66
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GNOG.L vs. URNG.L - Sharpe Ratio Comparison

The current GNOG.L Sharpe Ratio is 2.16, which is higher than the URNG.L Sharpe Ratio of 1.31. The chart below compares the historical Sharpe Ratios of GNOG.L and URNG.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GNOG.L	URNG.L	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.16	1.31	+0.85
Sharpe Ratio (All Time) Calculated using the full available price history	-0.36	0.52	-0.88

Drawdowns

GNOG.L vs. URNG.L - Drawdown Comparison

The maximum GNOG.L drawdown since its inception was -67.50%, which is greater than URNG.L's maximum drawdown of -38.98%. Use the drawdown chart below to compare losses from any high point for GNOG.L and URNG.L.

Drawdown Indicators

	GNOG.L	URNG.L	Difference
Max Drawdown Largest peak-to-trough decline	-67.50%	-38.98%	-28.52%
Max Drawdown (1Y) Largest decline over 1 year	-17.16%	-32.59%	+15.43%
Max Drawdown (3Y) Largest decline over 3 years	-47.97%	-38.98%	-8.99%
Current Drawdown Current decline from peak	-41.78%	-13.93%	-27.85%
Average Drawdown Average peak-to-trough decline	-44.20%	-12.79%	-31.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.79%	12.75%	-5.96%

Volatility

GNOG.L vs. URNG.L - Volatility Comparison

The current volatility for Global X Genomics & Biotechnology UCITS ETF (GNOG.L) is 7.97%, while Global X Uranium UCITS ETF USD Accumulating (URNG.L) has a volatility of 14.89%. This indicates that GNOG.L experiences smaller price fluctuations and is considered to be less risky than URNG.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GNOG.L	URNG.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.97%	14.89%	-6.92%
Volatility (6M) Calculated over the trailing 6-month period	19.73%	33.87%	-14.14%
Volatility (1Y) Calculated over the trailing 1-year period	27.38%	49.10%	-21.72%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	31.21%	39.66%	-8.45%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	31.21%	39.66%	-8.45%

GNOG.L vs. URNG.L - Expense Ratio Comparison

GNOG.L has a 0.50% expense ratio, which is lower than URNG.L's 0.65% expense ratio.

Dividends

GNOG.L vs. URNG.L - Dividend Comparison

Neither GNOG.L nor URNG.L has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both GNOG.L and URNG.L in my portfolio?

GNOG.L and URNG.L have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, GNOG.L or URNG.L?

On fees, GNOG.L is cheaper at 0.50% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, GNOG.L or URNG.L?

GNOG.L is cheaper with a 0.50% expense ratio, compared with 0.65% for URNG.L.

What is the main difference between GNOG.L and URNG.L?

GNOG.L is categorized as Health & Biotech Equities, while URNG.L is Commodity Producers Equities. GNOG.L tracks MSCI World/Health Care NR USD, while URNG.L tracks Solactive Global Uranium & Nuclear Components. Their fees differ too: 0.50% for GNOG.L and 0.65% for URNG.L.